Full Press Release Details
Positive Results of Above 95% For Preventing Bloodstream Infections
The ex-vivo testing demonstrated significant bacterial
reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients
Ra'anana, Israel - February 11, 2025 - Inspira
Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support
technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop
a novel bio-electronic treatment for preventing bloodstream infections.
In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated
a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which
uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.
"We believe that these initial results represent an important
milestone in our development of next-generation infection prevention technology," said Dagi Ben-Noon, CEO of Inspira. "With
an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach
could potentially offer significant advantages in critical care settings."
The bio-electronic technology is being designed to address several
key challenges associated with traditional IV dressings, including:
Testing was conducted following adjusted standardized protocols, including
the AATCC TM100 standard for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared
About Ennocure MedTech Ltd.
Ennocure, is a pioneer in the development of bio-electronic wound dressing.
At the core of the technology is a proprietary bio-electronic wound dressing designed to prevent bacterial infections, while providing
remote wound monitoring & infection alerts based on AI-driven personalized therapy.
Inspira is an innovative medical technology company in the life support
and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), a groundbreaking
device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute
respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART system aims to revolutionize critical
care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared
INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary
Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed
to provide continuous, real-time blood monitoring without the need for blood draws, targeting the $2.5 billion blood gas analyzer market.
The Company's pipeline products, including the INSPIRA ART (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor,
are currently in development and have not yet received regulatory approval.
For more information, please visit our corporate website at https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the potential benefits of its bio-electronic patch, that the initial results represent an important milestone in its development
of next-generation infection prevention technology and the intended design of the bio-electronic patch. These forward-looking statements
and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except
as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Inspira Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk